1-18 of 18
Elizabeth Fox
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children’s Oncology Group Phase I Consortium Trial

Available to Purchase
Adam L. Green, Charles G. Minard, Xiaowei Liu, Stephanie L. Safgren, Kerice Pinkney, Lauren Harris, Gabrielle Link, John DeSisto, Stephan Voss, Marvin D. Nelson, Joel M. Reid, Elizabeth Fox, Brenda J. Weigel, Julia Glade Bender
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (9): 1587–1595.
https://doi.org/10.1158/1078-0432.CCR-24-2754
Published: 01 May 2025
View articletitled, Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children’s Oncology Group Phase I Consortium Trial
Open the PDF for Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children’s Oncology Group Phase I Consortium Trial in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

Available to Purchase
Kara L. Davis, Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard, Stephan Voss, Stacey L. Berg, Brenda J. Weigel, Crystal L. Mackall
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (23): 5088–5097.
https://doi.org/10.1158/1078-0432.CCR-22-2164
Published: 01 December 2022
View articletitled, A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412
Open the PDF for A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 in another window
Includes: Supplementary data
Journal Articles

Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)

Free
Jennifer H. Foster, Stephan D. Voss, David C. Hall, Charles G. Minard, Frank M. Balis, Keith Wilner, Stacey L. Berg, Elizabeth Fox, Peter C. Adamson, Susan M. Blaney, Brenda J. Weigel, Yael P. Mossé
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (13): 3543–3548.
https://doi.org/10.1158/1078-0432.CCR-20-4224
Published: 01 July 2021
View articletitled, Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)
Open the PDF for Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) in another window
Includes: Supplementary data
Journal Articles

Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting

Available to Purchase
Navid Hafez, Hope S. Rugo, Margaret A. Tempero, Elizabeth Fox, Gregory H. Reaman, Herbert Kim Lyerly, Desiree Walker, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4743–4747.
https://doi.org/10.1158/1078-0432.CCR-19-4035
Published: 15 September 2020
View articletitled, Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting
Open the PDF for Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting in another window
Journal Articles

Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

Available to Purchase
Kristina A. Cole, Sharmistha Pal, Rachel A. Kudgus, Heba Ijaz, Xiaowei Liu, Charles G. Minard, Bruce R. Pawel, John M. Maris, Daphne A. Haas-Kogan, Stephan D. Voss, Stacey L. Berg, Joel M. Reid, Elizabeth Fox, Brenda J. Weigel
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (6): 1213–1219.
https://doi.org/10.1158/1078-0432.CCR-19-3470
Published: 13 March 2020
View articletitled, Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)
Open the PDF for Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312) in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

Free
Yael P. Mossé, Elizabeth Fox, David T. Teachey, Joel M. Reid, Stephanie L. Safgren, Hernan Carol, Richard B. Lock, Peter J. Houghton, Malcolm A. Smith, David Hall, Donald A. Barkauskas, Mark Krailo, Stephan D. Voss, Stacey L. Berg, Susan M. Blaney, Brenda J. Weigel
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (11): 3229–3238.
https://doi.org/10.1158/1078-0432.CCR-18-2675
Published: 03 June 2019
View articletitled, A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Open the PDF for A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Free
Steven G. DuBois, Yael P. Mosse, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid, Renee McGovern, Susan Groshen, Rochelle Bagatell, John M. Maris, Clare J. Twist, Kelly Goldsmith, M. Meaghan Granger, Brian Weiss, Julie R. Park, Margaret E. Macy, Susan L. Cohn, Greg Yanik, Lars M. Wagner, Randall Hawkins, Jesse Courtier, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Najee Boucher, Scarlett Czarnecki, Chunqiao Luo, Denice Tsao-Wei, Katherine K. Matthay, Araz Marachelian
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6142–6149.
https://doi.org/10.1158/1078-0432.CCR-18-1381
Published: 13 December 2018
View articletitled, Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Open the PDF for Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib

Free
Ira L. Kraft, Srivandana Akshintala, Yuelin Zhu, Haiyan Lei, Claudia Derse-Anthony, Eva Dombi, Seth M. Steinberg, Maya Lodish, Steven G. Waguespack, Oxana Kapustina, Elizabeth Fox, Frank M. Balis, Maria J. Merino, Paul S. Meltzer, John W. Glod, Jack F. Shern, Brigitte C. Widemann
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (4): 753–765.
https://doi.org/10.1158/1078-0432.CCR-17-2101
Published: 14 February 2018
View articletitled, Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
Open the PDF for Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib in another window
Includes: Supplementary data
Journal Articles

Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report

Free
Sarah E.S. Leary, Julie R. Park, Joel M. Reid, Andrew T. Ralya, Sylvain Baruchel, Bing Wu, Timothy P.L. Roberts, Xiaowei Liu, Charles G. Minard, Elizabeth Fox, Brenda Weigel, Susan Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6062–6069.
https://doi.org/10.1158/1078-0432.CCR-16-2882
Published: 12 October 2017
View articletitled, Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report
Open the PDF for Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report in another window
Journal Articles

Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma

Free
Elizabeth Fox, Brigitte C. Widemann, Meredith K. Chuk, Leigh Marcus, Alberta Aikin, Patricia O. Whitcomb, Maria J. Merino, Maya Lodish, Eva Dombi, Seth M. Steinberg, Samuel A. Wells, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4239–4248.
https://doi.org/10.1158/1078-0432.CCR-13-0071
Published: 31 July 2013
View articletitled, Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
Open the PDF for Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma in another window
Includes: Supplementary data
Journal Articles

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

Free
Yael P. Mossé, Emily Lipsitz, Elizabeth Fox, David T. Teachey, John M. Maris, Brenda Weigel, Peter C. Adamson, Mark A. Ingle, Charlotte H. Ahern, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 6058–6064.
https://doi.org/10.1158/1078-0432.CCR-11-3251
Published: 06 November 2012
View articletitled, Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
Open the PDF for Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study in another window
Journal Articles

A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report

Free
Brigitte C. Widemann, AeRang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda Weigel, Diana Stempak, Frank M. Balis, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 6011–6022.
https://doi.org/10.1158/1078-0432.CCR-11-3284
Published: 06 November 2012
View articletitled, A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report
Open the PDF for A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report in another window
Includes: Supplementary data
Journal Articles

Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials

Free
AeRang Kim, Eva Dombi, Jeffrey Solomon, Elizabeth Fox, Frank M. Balis, Brigitte C. Widemann
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (18): 5982–5990.
https://doi.org/10.1158/1078-0432.CCR-10-2259
Published: 14 September 2011
View articletitled, Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials
Open the PDF for Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials in another window
Journal Articles

Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group

Free
Shana Jacobs, Elizabeth Fox, Mark Krailo, Gwen Hartley, Fariba Navid, Leonard Wexler, Susan M. Blaney, Anne Goodwin, Wendy Goodspeed, Frank M. Balis, Peter C. Adamson, Brigitte C. Widemann
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (2): 750–754.
https://doi.org/10.1158/1078-0432.CCR-09-1906
Published: 14 January 2010
View articletitled, Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group
Open the PDF for Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group in another window
Journal Articles

Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas

Free
Elizabeth Fox, Brigitte C. Widemann, Douglas S. Hawkins, Nalini Jayaprakash, Ramzi Dagher, Alberta A. Aikin, Donna Bernstein, Lauren Long, Crystal Mackall, Lee Helman, Seth M. Steinberg, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7361–7367.
https://doi.org/10.1158/1078-0432.CCR-09-0761
Published: 30 November 2009
View articletitled, Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas
Open the PDF for Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas in another window
Journal Articles

A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors

Free
Elizabeth Fox, John M. Maris, Brigitte C. Widemann, Wendy Goodspeed, Anne Goodwin, Marie Kromplewski, Molly E. Fouts, Diane Medina, Susan L. Cohn, Andrew Krivoshik, Anne E. Hagey, Peter C. Adamson, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (4): 1111–1115.
https://doi.org/10.1158/1078-0432.CCR-07-4097
Published: 15 February 2008
View articletitled, A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors
Open the PDF for A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors in another window
Journal Articles

A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors

Free
Elizabeth Fox, John M. Maris, Brigitte C. Widemann, Kysa Meek, Anne Goodwin, Wendy Goodspeed, Marie Kromplewski, Molly E. Fouts, Diane Medina, Steve Y. Cho, Susan L. Cohn, Andrew Krivoshik, Anne E. Hagey, Peter C. Adamson, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (16): 4882–4887.
https://doi.org/10.1158/1078-0432.CCR-06-0534
Published: 16 August 2006
View articletitled, A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors
Open the PDF for A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors in another window
Journal Articles

Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates

Free
Shana S. Jacobs, Elizabeth Fox, Christopher Dennie, Lindsey B. Morgan, Cynthia L. McCully, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (4): 1669–1674.
https://doi.org/10.1158/1078-0432.CCR-04-1807
Published: 02 March 2005
View articletitled, Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates
Open the PDF for Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates in another window